Skip to main content

01.06.2006 | Original article

The protective effects of incadronate on inflammation and joint destruction in established rat adjuvant arthritis

verfasst von: Hongpu Zhao, Shangli Liu, Dongsheng Huang, Qiuyu Xu, Toshihide Shuto, Yukihide Iwamoto

Erschienen in: Rheumatology International | Ausgabe 8/2006

Einloggen, um Zugang zu erhalten

Abstract

The effects of a new generation bisphosphonate, incadronate, in established adjuvant arthritis rats were evaluated according to the arthritis index, hind paw volume, and radiological and histopathological examinations. Incadronate suppressed the radiological and histopathological changes of hind paws, as well as the joint swelling in a dose-dependent manner. In contrast, the arthritis control rats showed drastic joint inflammation, marked destruction of bone and articular cartilage. The remains of articular cartilage lost Safranin O staining, and were attached with numerous TRAP-positive multinuclear cells. Some of resorption lacunas could be seen at the cartilage matrix nearby the TRAP-positive multinuclear cells. As regards the chondroprotective effects of bisphosphonates, we speculate that it is probably concerned with the inhibition of the chondroclasts. These data indicate that bisphosphonates may be a class of effective agent that can be considered for treatment of various arthritic conditions, including human rheumatoid arthritis.
Literatur
1.
2.
Zurück zum Zitat Harinck HI, Papapoulos SE, Blanksma HJ, Moolenaar AJ, Vermeij P, Bijvoet OL (1987) Paget’s disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD). Br Med J 295:1301–1305 Harinck HI, Papapoulos SE, Blanksma HJ, Moolenaar AJ, Vermeij P, Bijvoet OL (1987) Paget’s disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD). Br Med J 295:1301–1305
3.
Zurück zum Zitat Thiebaud D, Jaeger P, Gobelet C, Jacquet AF, Burckhardt P (1988) A single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget’s disease of bone. Am J Med 85:207–212PubMedCrossRef Thiebaud D, Jaeger P, Gobelet C, Jacquet AF, Burckhardt P (1988) A single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget’s disease of bone. Am J Med 85:207–212PubMedCrossRef
4.
Zurück zum Zitat Body JJ, Mancini I (2003) Treatment of tumor-induced hypercalcemia: a solved problem? Expert Rev Anticancer Ther 3:241–246PubMedCrossRef Body JJ, Mancini I (2003) Treatment of tumor-induced hypercalcemia: a solved problem? Expert Rev Anticancer Ther 3:241–246PubMedCrossRef
5.
Zurück zum Zitat Body JJ (2000) Current and future directions in medical therapy: hypercalcemia. Cancer 88(Suppl):3054–3058PubMedCrossRef Body JJ (2000) Current and future directions in medical therapy: hypercalcemia. Cancer 88(Suppl):3054–3058PubMedCrossRef
6.
Zurück zum Zitat Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH (1990) Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 322:1265–1271PubMed Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH (1990) Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 322:1265–1271PubMed
7.
Zurück zum Zitat Eggelmeijer F, Papapoulos SE, van Paassen HC, Dijkmans BA, Breedveld FC (1994) Clinical and biochemical response to single infusion of pamidronate in patients with active rheumatoid arthritis: a double blind placebo controlled study. J Rheumatol 21:2016–2020PubMed Eggelmeijer F, Papapoulos SE, van Paassen HC, Dijkmans BA, Breedveld FC (1994) Clinical and biochemical response to single infusion of pamidronate in patients with active rheumatoid arthritis: a double blind placebo controlled study. J Rheumatol 21:2016–2020PubMed
8.
Zurück zum Zitat Cantatore FP, Acquista CA, Pipitone V (1999) Evaluation of bone turnover and osteoclastic cytokines in early rheumatoid arthritis treated with alendronate. J Rheumatol 26:2318–2323PubMed Cantatore FP, Acquista CA, Pipitone V (1999) Evaluation of bone turnover and osteoclastic cytokines in early rheumatoid arthritis treated with alendronate. J Rheumatol 26:2318–2323PubMed
9.
Zurück zum Zitat Havdrup T, Hulth A, Telhag H (1976) The subchondral bone in osteoarthritis and rheumatoid arthritis of the knee. A histological and microradiographical study. Acta Orthop Scand 47:345–350PubMedCrossRef Havdrup T, Hulth A, Telhag H (1976) The subchondral bone in osteoarthritis and rheumatoid arthritis of the knee. A histological and microradiographical study. Acta Orthop Scand 47:345–350PubMedCrossRef
10.
Zurück zum Zitat Bromley M, Woolley DE (1984) Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. Arthritis Rheum 27:968–975PubMedCrossRef Bromley M, Woolley DE (1984) Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. Arthritis Rheum 27:968–975PubMedCrossRef
11.
Zurück zum Zitat Eggelmeijer F, Papapoulos SE, van Paassen HC, Dijkmans BA, Valkema R, Westedt ML, Landman JO, Pauwels EK, Breedveld FC (1996) Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial. Arthritis Rheum 39:396–402PubMedCrossRef Eggelmeijer F, Papapoulos SE, van Paassen HC, Dijkmans BA, Valkema R, Westedt ML, Landman JO, Pauwels EK, Breedveld FC (1996) Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial. Arthritis Rheum 39:396–402PubMedCrossRef
12.
Zurück zum Zitat Maccagno A, Di GE, Roldan EJ, Caballero LE, Perez LA (1994) Double blind radiological assessment of continuous oral pamidronic acid in patients with rheumatoid arthritis. Scand J Rheumatol 23:211–214PubMedCrossRef Maccagno A, Di GE, Roldan EJ, Caballero LE, Perez LA (1994) Double blind radiological assessment of continuous oral pamidronic acid in patients with rheumatoid arthritis. Scand J Rheumatol 23:211–214PubMedCrossRef
13.
Zurück zum Zitat Barbier A, Breliere JC, Remandet B, Roncucci R (1986) Studies on the chronic phase of adjuvant arthritis: effect of SR 41319, a new diphosphonate. Ann Rheum Dis 45:67–74PubMedCrossRef Barbier A, Breliere JC, Remandet B, Roncucci R (1986) Studies on the chronic phase of adjuvant arthritis: effect of SR 41319, a new diphosphonate. Ann Rheum Dis 45:67–74PubMedCrossRef
14.
Zurück zum Zitat Osterman T, Kippo K, Lauren L, Hannuniemi R, Sellman R (1994) Effect of clodronate on established adjuvant arthritis. Rheumatol Int 14:139–147PubMedCrossRef Osterman T, Kippo K, Lauren L, Hannuniemi R, Sellman R (1994) Effect of clodronate on established adjuvant arthritis. Rheumatol Int 14:139–147PubMedCrossRef
15.
Zurück zum Zitat Podworny NV, Kandel RA, Renlund RC, Grynpas MD (1999) Partial chondroprotective effect of zoledronate in a rabbit model of inflammatory arthritis. J Rheumatol 26:1972–1982PubMed Podworny NV, Kandel RA, Renlund RC, Grynpas MD (1999) Partial chondroprotective effect of zoledronate in a rabbit model of inflammatory arthritis. J Rheumatol 26:1972–1982PubMed
16.
Zurück zum Zitat Zhao H, Shuto T, Hirata G, Iwamoto Y (2000) Aminobisphosphonate (YM175) inhibits bone destruction in rat adjuvant arthritis. J Orthop Sci 5:397–403PubMed Zhao H, Shuto T, Hirata G, Iwamoto Y (2000) Aminobisphosphonate (YM175) inhibits bone destruction in rat adjuvant arthritis. J Orthop Sci 5:397–403PubMed
17.
Zurück zum Zitat Matsuo A, Shuto T, Hirata G, Satoh H, Matsumoto Y, Zhao H, Iwamoto Y (2003) Antiinflammatory and chondroprotective effects of the aminobisphosphonate incadronate (YM175) in adjuvant induced arthritis. J Rheumatol 30:1280–1290PubMed Matsuo A, Shuto T, Hirata G, Satoh H, Matsumoto Y, Zhao H, Iwamoto Y (2003) Antiinflammatory and chondroprotective effects of the aminobisphosphonate incadronate (YM175) in adjuvant induced arthritis. J Rheumatol 30:1280–1290PubMed
18.
Zurück zum Zitat Kinne RW, Schmidt-Weber CB, Hoppe R, Buchner E, Palombo-Kinne E, Nurnberg E, Emmrich F (1995) Long-term amelioration of rat adjuvant arthritis following systemic elimination of macrophages by clodronate-containing liposomes. Arthritis Rheum 38:1777–1790PubMedCrossRef Kinne RW, Schmidt-Weber CB, Hoppe R, Buchner E, Palombo-Kinne E, Nurnberg E, Emmrich F (1995) Long-term amelioration of rat adjuvant arthritis following systemic elimination of macrophages by clodronate-containing liposomes. Arthritis Rheum 38:1777–1790PubMedCrossRef
19.
Zurück zum Zitat Nishikawa M, Akatsu T, Katayama Y, Yasutomo Y, Kado S, Kugal N, Yamamoto M, Nagata N (1996) Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Bone 18:9–14PubMedCrossRef Nishikawa M, Akatsu T, Katayama Y, Yasutomo Y, Kado S, Kugal N, Yamamoto M, Nagata N (1996) Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Bone 18:9–14PubMedCrossRef
20.
Zurück zum Zitat Nishikawa M, Yamamoto M, Murakami T, Akatsu T, Kugai N, Nagata N (1998) A third-generation bisphosphonate, YM175, inhibits osteoclast formation in murine cocultures by inhibiting proliferation of precursor cells via supporting cell-dependent mechanisms. J Bone Miner Res13:986–995CrossRef Nishikawa M, Yamamoto M, Murakami T, Akatsu T, Kugai N, Nagata N (1998) A third-generation bisphosphonate, YM175, inhibits osteoclast formation in murine cocultures by inhibiting proliferation of precursor cells via supporting cell-dependent mechanisms. J Bone Miner Res13:986–995CrossRef
21.
Zurück zum Zitat Ito M, Amizuka N, Nakajima T, Ozawa H (1999) Ultrastructural and cytochemical studies on cell death of osteoclasts induced by bisphosphonate treatment. Bone 25:447–452PubMedCrossRef Ito M, Amizuka N, Nakajima T, Ozawa H (1999) Ultrastructural and cytochemical studies on cell death of osteoclasts induced by bisphosphonate treatment. Bone 25:447–452PubMedCrossRef
22.
Zurück zum Zitat Lehmann HJ, Mouritzen U, Christgau S, Cloos PA, Christiansen C (2002) Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products. Ann Rheum Dis 61:530–533PubMedCrossRef Lehmann HJ, Mouritzen U, Christgau S, Cloos PA, Christiansen C (2002) Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products. Ann Rheum Dis 61:530–533PubMedCrossRef
23.
Zurück zum Zitat Garnero P, Christgau S, Delmas PD (2001) The bisphosphonate zoledronate decreases type II collagen breakdown in patients with Paget’s disease of bone. Bone 28:461–464PubMedCrossRef Garnero P, Christgau S, Delmas PD (2001) The bisphosphonate zoledronate decreases type II collagen breakdown in patients with Paget’s disease of bone. Bone 28:461–464PubMedCrossRef
24.
Zurück zum Zitat Teronen O, Heikkila P, Konttinen YT, Laitinen M, Salo T, Hanemaaijer R, Teronen A, Maisi P, Sorsa T (1999) MMP inhibition and downregulation by bisphosphonates. Ann N Y Acad Sci 878:453–465PubMedCrossRef Teronen O, Heikkila P, Konttinen YT, Laitinen M, Salo T, Hanemaaijer R, Teronen A, Maisi P, Sorsa T (1999) MMP inhibition and downregulation by bisphosphonates. Ann N Y Acad Sci 878:453–465PubMedCrossRef
25.
Zurück zum Zitat Van Offel JF, Schuerwegh AJ, Bridts CH, Stevens WJ, De Clerck LS (2002) Effect of bisphosphonates on viability, proliferation, and dexamethasone-induced apoptosis of articular chondrocytes. Ann Rheum Dis 61:925–928PubMedCrossRef Van Offel JF, Schuerwegh AJ, Bridts CH, Stevens WJ, De Clerck LS (2002) Effect of bisphosphonates on viability, proliferation, and dexamethasone-induced apoptosis of articular chondrocytes. Ann Rheum Dis 61:925–928PubMedCrossRef
26.
Zurück zum Zitat Johnson WJ, DiMartino MJ, Hanna N (1986) Macrophage activation in rat models of inflammation and arthritis: determination of markers of stages of activation. Cell Immunol 103:54–64PubMedCrossRef Johnson WJ, DiMartino MJ, Hanna N (1986) Macrophage activation in rat models of inflammation and arthritis: determination of markers of stages of activation. Cell Immunol 103:54–64PubMedCrossRef
27.
Zurück zum Zitat Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13:581–589PubMedCrossRef Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13:581–589PubMedCrossRef
28.
Zurück zum Zitat Nakamura M, Ando T, Abe M, Kumagai K, Endo Y (1996) Contrast between effects of aminobisphosphonates and non-aminobisphosphonates on collagen-induced arthritis in mice. Br J Pharmacol 119:205–212PubMed Nakamura M, Ando T, Abe M, Kumagai K, Endo Y (1996) Contrast between effects of aminobisphosphonates and non-aminobisphosphonates on collagen-induced arthritis in mice. Br J Pharmacol 119:205–212PubMed
29.
Zurück zum Zitat Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB (2001) Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 28:524–531PubMedCrossRef Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB (2001) Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 28:524–531PubMedCrossRef
30.
Zurück zum Zitat Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB (2000) Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15:613–620PubMedCrossRef Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB (2000) Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15:613–620PubMedCrossRef
31.
Zurück zum Zitat Komatsubara S, Mori S, Mashiba T, Ito M, Li J, Kaji Y, Akiyama T, Miyamoto K, Cao Y, Kawanishi J, Norimatsu H (2003) Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra. J Bone Miner Res 18:512–520PubMedCrossRef Komatsubara S, Mori S, Mashiba T, Ito M, Li J, Kaji Y, Akiyama T, Miyamoto K, Cao Y, Kawanishi J, Norimatsu H (2003) Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra. J Bone Miner Res 18:512–520PubMedCrossRef
Metadaten
Titel
The protective effects of incadronate on inflammation and joint destruction in established rat adjuvant arthritis
verfasst von
Hongpu Zhao
Shangli Liu
Dongsheng Huang
Qiuyu Xu
Toshihide Shuto
Yukihide Iwamoto
Publikationsdatum
01.06.2006
Verlag
Springer-Verlag
Erschienen in
Rheumatology International / Ausgabe 8/2006
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-005-0061-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.